News

News Archive

Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24

Selvita S.A. (WSE:SLV), and Berlin-Chemie Menarini, a company of the Menarini Group, announced today that both companies have entered into a global license agreement for SEL24, a dual...
Excellences of the territory, the Mayor Fabio Fucci in visit to the Campus of Research Menarini in Pomezia

Excellences of the territory, the Mayor Fabio Fucci in visit to the Campus of Research Menarini in Pomezia

Excellences of the territory, the Mayor Fabio Fucci in visit to the Campus of Research Menarini in Pomezia

Melinta Therapeutics and Menarini Group Enter into  Commercial and Co-Development Agreement for Delafloxacin in 68 Countries

Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries

Melinta Therapeutics and Menarini Group today announced the signing of a development and commercialization agreement. As part of this agreement, Melinta has granted the Menarini Group...

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Follow our blog

Discover our stories from all over the world

Read More